The hedgehog (Hh) signaling pathway regulates the development of many organs in mammals, and activation of this pathway is widely observed in human cancers. Although it is known that Hh signaling activates the expression of genes involved in cell growth, the precise role of the Hh pathway in cancer development is still unclear. Here, we show that constitutively activated mutants of oncogenesis ͉ ubiquitination ͉ cell growth ͉ apoptosis
T he hedgehog (Hh) signaling pathway directs tissue patterning during embryonic development and stem cell maintenance (1) (2) (3) . By binding to its receptor, Patched (Ptch), Hh is able to alleviate Ptch-mediated suppression of Smoothened (Smo). Activated Smo subsequently induces the activation of Gli family transcription factors by causing the dissociation of cytoplasmic inhibitory proteins, including Suppressor of Fused (SuFu), resulting in the transcriptional activation of Gli target genes (3) . Accumulating evidence has shown that uncontrolled activation of the Hh signaling pathway results in distinct cancers. Constitutive activation of this pathway in human cancers is caused by genetic mutations of its molecular components, such as loss-offunction mutations in negative pathway regulators, for example Ptch and SuFu, and gain-of-function mutations in Smo (1, 4) . These genetic alterations are mainly observed in basal-cell carcinomas (BCCs) and medulloblastomas. Recently, it was shown that Hh signaling activation due to the overproduction of the Hh ligands Sonic hedgehog (Shh) and Indian hedgehog (Ihh) is widely observed in human cancers, including cancers of the esophagus, stomach, pancreas, and lungs, suggesting a role for Hh signaling in oncogenesis (5) (6) (7) (8) .
The p53 tumor suppressor gene is the most common target of genetic alterations in human cancers (9) . The p53 protein is highly unstable and is constitutively degraded by the ubiquitinproteasome system (10) . In response to DNA damage, p53 is covalently modified and stabilized, resulting in its accumulation (11) . Recently, it has been shown that activation of oncogenes evokes a DNA damage response resulting in p53 activation. During the early tumorigenic stages, aberrant oncogene activation can give rise to ''oncogenic stress,'' which evokes a p53-mediated counterresponse to eliminate hazardous cells (12, 13) through the induction of apoptosis or senescence (14, 15) . Therefore, during oncogenesis, p53 inhibition is crucial for the survival and maintenance of such oncogene-expressing cells.
In the present study, we determined that activation of Hh signaling inhibits the accumulation of p53 at the basal level and in response to DNA damage. We also found that Hh signaling promotes p53 ubiquitination mediated by Mdm2. Moreover, Hh signaling inhibited p53-dependent apoptosis and growth arrest in oncogene-expressing mouse embryonic fibroblasts (MEFs). These results suggest that Hh signaling accelerates oncogenesis through activation of cell proliferation and inhibition of p53-mediated tumor suppression.
Results
Hh Signaling Down-Regulates p53. Previously, two activating somatic missense mutations of Smo, SMO-M1 (Arg-562 to Gln) and SMO-M2 (Trp-535 to Leu), were identified in sporadic BCCs (16) . Interestingly, it was shown that the Smo mutants act in conjunction with adenovirus E1A to transform rat embryonic fibroblasts (16) . Conversely, it has been shown that E1A strongly sensitizes primary fibroblasts to apoptosis in response to DNA damage and that this apoptosis is largely dependent on p53 (17, 18) . These observations raise the possibility that Smo mutants inhibit p53 activity. To test this hypothesis, cells were cotransfected with expression vectors for SMO-M1 or SMO-M2, a p53-expression vector and a p53-responsive luciferase reporter plasmid. As shown in Fig. 1a , SMO-M1 and SMO-M2 efficiently inhibited p53-mediated transcription in p53-null human Saos-2 cells. The same effect was also observed in murine C3H10T1/2 cells (Fig. 1b) , which are widely used to analyze Hh signaling (19) ; moreover, the endogenous WT p53 of C3H10T1/2 cells was inhibited by WT Smo. Overexpression of SMO-M1 and SMO-M2 markedly decreased the amount of ectopically expressed p53 (Fig. 1c ) and endogenous p53 (Fig. 1d) . The amount of endogenous p53 also decreased after overexpression of WT Smo (Fig. 1d) . Furthermore, Shh decreased the expression level of endogenous p53 (Fig. 1e) . (Fig. 2a) , suggesting that Hh signaling inhibits p53 accumulation. Indeed, the Smo mutants-mediated decreases in p53 expression level were significantly reversed in the presence of the proteasome inhibitor MG132 (Fig. 2b) . Moreover, expression of Smo mutants augmented the ubiquitination of p53 (Fig. 2c) , suggesting that Hh signaling accelerates p53 degradation through the ubiquitin-proteasome system. Shh also enhanced ubiquitination of exogenously expressed p53 (Fig. 2d ) and endogenous p53 (Fig.  2e ). p53 ubiquitination has been shown to be mediated by multiple E3 ubiquitin ligases, including Mdm2, Pirh2 (20) , and COP1 (21) . However, Smo mutant expression did not increase the mRNA levels of these ligases (Fig. 2a) . We then analyzed the role of Mdm2 in the p53-related effects of the Hh pathway. Mdm2 associates with p53, resulting in the ubiquitination and cytoplasmic export of p53 from the nucleus (11) . As shown in Fig. 2 f and g, expression of Smo mutants induced the cytoplasmic translocation of p53 from the nucleus. Moreover, the binding of p53 to Mdm2 was augmented in the presence of Smo mutants (Fig. 2h) , offering a molecular explanation for its elevated ubiquitination. Indeed, enhanced p53 ubiquitination induced by Smo mutants was clearly suppressed by the RNAi-mediated suppression of Mdm2, using an shRNA expression system (Fig.  2i) . Moreover, the Mdm2 antagonist Nutlin-3 inhibited the Smo mutant-mediated decrease in p53 expression (Fig. 2j) , suggesting that Hh signaling activates the Mdm2-mediated degradation of p53.
Hh Signaling Induces Activating Phosphorylation of Mdm2. The phosphorylation of two serine residues, S166 and S186, of human Mdm2 (Hdm2) was enhanced by the expression of Smo mutants (Fig. 3a) . S166 and S186 are known to be phosphorylated by Akt, which activates the Mdm2-mediated degradation of p53 (22, 23) . Recently, it was reported that Smo activates phosphoinositide 3-kinase (PI3K) and Akt, both of which belong to an essential Shh signaling pathway (24) . As shown in Fig. 3b , Shh slightly enhanced the phosphorylation of Akt (S473) and decreased p53 expression; however, the Shh-mediated reduction in p53 expression was suppressed by the PI3K inhibitor LY294002. In the Hh signaling pathway, the activation of Smo results in the activation of Gli family transcription factors (25) . It was also shown that the PI3K/Akt pathway activates Glis (24) . In the context of cancer, Gli1 was originally identified to be amplified in human gliomas; the ectopic expression of Gli1 or Gli2 in the skin results in tumor formation in mice (26, 27) . Interestingly, forced expression of Gli1 or Gli2 decreased endogenous p53 expression, and this effect was suppressed by MG132 ( Fig. 3 c and d) , suggesting that Gli1 and Gli2 induce ubiquitin-mediated p53 degradation. By contrast, forced expression of Gli3 had no effect (Fig. 3e) . The involvement of Gli in this system was also confirmed by inhibition of the SMO-M2-mediated decrease in p53 expression induced by SuFu, a negative regulator of Gli activation by Hh signaling (Fig. 3f ) . Moreover, phosphorylation of S166 and S186 was also enhanced in the presence of Shh, but inhibited by the protein synthesis blocker cycloheximide (Fig. 3g) . Therefore, these results suggest that Hh signaling augments p53 protein degradation by direct phosphorylation of Mdm2 through a Gli-induced factor(s). (17, 18) . Therefore, we next evaluated the effect of mutant Smo on E1A-expressing MEFs treated with adriamycin. Indeed, SMO-M1 and SMO-M2 expression in E1A-expressing MEFs led to the attenuation of adriamycin-induced apoptosis (Fig. 4c) . It is also known that oncogenic ras induces p53-dependent premature cell senescence (18) . As shown in Fig. 4d , oncogenic ras (V12 Ras)-induced growth suppression was also inhibited by SMO-M1 and SMO-M2 expression.
Hh signaling activates the expression of genes involved in cell proliferation, such as cyclins D and E (28). Indeed, Smo mutants enhanced cyclin D1 and E expression in MEFs (Fig. 4e) , and also increased the rate of proliferation of these cells (Fig. 4f ) . Recently, it was suggested that deregulated expression of oncogenes might evoke a DNA-damage response, resulting in p53 activation (12, 13) . Interestingly, Smo mutants induced a DNAdamage response, evidenced by the activation of ATM and the phosphorylation of histone H2AX (Fig. 4g) . These results suggest that Hh signaling activates cell proliferation and enhances DNA damage responses; however, at the same time, p53-mediated tumor suppression was inhibited through the activation of Mdm2. We also analyzed cell transformation, using V12 Ras and Smo mutants. Although V12 Ras and Smo mutantexpressing WT MEFs did not show anchorage-independent colony formation in soft agar, Smo mutants enhanced the V12 Ras-induced transformation of p53 heterozygote (p53 ϩ/Ϫ ) MEFs (Fig. 4h) , suggesting that Hh signaling inhibits p53-mediated tumor suppression. In addition, Smo mutants enhanced colony formation by V12 Ras-expressing p53-null (p53 Ϫ/Ϫ ) MEFs, suggesting that some Smo mutant-mediated oncogenic function, for example, activation of cyclins D1 and E, enhances V12 Ras-induced cell transformation (Fig. 4h) .
Inhibition of Hh Signaling Recovers p53 Expression and Function in
Breast Cancer Cell Lines. We next analyzed two human breast cancer cell lines containing WT p53 (29) . As shown in Fig. 5a , KAAD cyclopamine (30), a specific inhibitor of the Hh pathway, inhibited the expression of cyclins D1 and E. Moreover, KAAD cyclopamine treatment resulted in the accumulation of endogenous WT p53 (Fig. 5b) , suggesting that Hh signaling inhibited the production of p53. The growth of these two cell lines was efficiently inhibited by KAAD cyclopamine; however, this growth inhibition disappeared subsequent to p53 expression knockdown by RNAi, using an shRNA expression system ( Fig.   5 c-e). Furthermore, the DNA damage-induced apoptosis of YMB1E cells was accelerated by KAAD cyclopamine; however, this acceleration was clearly inhibited by p53 expression knockdown (Fig. 5f ). The acceleration of apoptosis by KAAD cyclopamine was not observed in MRK-nu-1 cells (data not shown), and the reason for this differential response is presently unknown. However, these results suggest that constitutive Hh signaling inhibits p53 accumulation in the tested human cancer cells.
Discussion
In this study, we found that Hh signaling inhibits p53-mediated tumor suppression by activating Mdm2. p53 functions as a critical tumor suppressor by activating the expression of genes that induce cell growth inhibition, apoptosis, and DNA repair (17, 31, 32) . Recent studies have clearly shown that oncogene activation evokes a DNA-damage response, which results in p53 activation (12, 13) . Moreover, many studies have shown that p53 induces apoptosis or replicative senescence in oncogene-expressing cells (17, 18, 31) , suggesting that the elimination of such cells is important for tumor suppression. Therefore, it is possible that escape from such a p53-mediated tumor surveillance system is important during the early stages of oncogenesis. In this context, Hh signaling is an interesting example with which to consider oncogenesis. Hh signaling induces cell growth by activating the expression of cyclins D1 and E (Fig. 4 e and f ) . At the same time, Hh signaling evokes a DNA-damage-induced signal (Fig. 4g) . This DNA-damageinduced signal may be caused by oncogenic stress (12, 13, 31, 32) ; however, at the same time, Hh signaling down-regulates p53 by activating Mdm2 (Figs. 1-3) . As a result, an important function of p53 in tumor suppression, the induction of apoptosis or senescence in oncogene-expressing cells, is partially inhibited (Fig. 4 c and d) . These results suggest that Hh signaling functions as an accelerator of oncogenesis, activating cell proliferation and, at the same time, inhibiting the p53-mediated anti-cancer barrier induced by oncogenic stress.
In this study, we showed that Hh signaling activates phosphorylation of Mdm2 at serines 166 and 186, which were identified as sites of activating phosphorylation by Akt (Fig. 3a  and refs. 22 and 23) . It was recently reported that Hh signaling activates PI3K and Akt (24) . Indeed, phosphorylation of these sites, induced by Hh signaling, is reduced by the PI3K inhibitor (Fig. 3b) . These results indicate that induction of the PI3K/Akt pathway by Hh signaling is involved in the activation of Mdm2. However, we also found that the forced expression of Gli1 or Gli2 reduced the amount of p53 in cells (Fig. 3 c and d) . This result was also supported by the findings that the forced expression of SuFu, a negative regulator of Gli activation in the Hh pathway, restored the Smo mutant-meditated reduction in the amount of p53 in cells (Fig. 3f ) , and that the phosphorylation of Mdm2 at serines 166 and 186 was inhibited by cycloheximide (Fig. 3g) , suggesting that de novo protein synthesis is important for these phosphorylation events. These results strongly suggest that a Gli-induced factor(s) underlies this phenomenon. At present, the kinase(s) directly induced or indirectly activated by Hh signaling remain to be identified. However, when considering oncogenesis, it is interesting that the oncogenic transcription factor Gli also decreased the amount of p53 in cells. Hdm2 and Gli1 genes are relatively close to each other on the same human chromosome, and they are sometimes coamplified in cancers (33) , suggesting that a combination of excess Gli1 together with excess Mdm2 is sufficient to efficiently inactivate p53.
Hh signaling has been implicated in tissue repair and the maintenance of stem or progenitor cells in adult tissues, including skin, blood, gut, prostate, muscle, and the nervous system (1-3). It is also well known that chronic tissue injury caused by inf lammation is associated with tumorigenesis (1). Moreover, recently, it was also shown that Hh signaling maintains a tumor stem cell compartment (34) . Therefore, it is possible that, in the early stage of tumorigenesis, Hh signaling promotes cell growth and partially inhibits p53 function, thereby enabling these cells to survive and grow. This model is also supported by a recent study that demonstrated cooperation of Hedgehog and Ras signaling during the earliest stages of pancreatic ductal adenocarcinoma formation in an animal model (35) . By contrast, the effect of Hh signaling in the inhibition of p53 is not complete, but partial (see Fig. 1 d and e and Fig. 4 a and b) . This partial effect is seen in the result showing that Smo mutants enhanced activated Ras-induced transformation in p53 heterozygote (p53 ϩ/Ϫ ) MEFs, but not in WT MEFs (Fig. 4h) , suggesting that activation of Hh signaling only is not sufficient for the inhibition of p53-mediated tumor suppression. This issue is also supported because mutations in both Ptch (or Smo) and p53 are often observed together in BCC tumors (36, 37) . We also showed that, in human breast cancer cell lines, the levels of p53 are decreased by activated Hh signaling and that inhibition of Hh signaling by KAAD cyclopamine results in accumulation of p53 (Fig. 5b) . Therefore, at least in some types of cancer, activation of the Hh signaling pathway partially abrogates the tumor suppressive effects of p53. Altogether, our observations imply that constitutive Hh pathway activation functions as an accelerator of oncogenesis and simultaneously induces cell proliferation by overriding p53-mediated tumor suppression.
Materials and Methods
Immunoprecipitation and Immunoblotting. To detect the amount of endogenous or transiently produced p53 protein, cells were lysed in RIPA buffer [1% Nonidet P-40, 0.5% sodium-deoxycholate, 0.1% SDS, 10 mM Tris⅐HCl (pH 8.0), 150 mM NaCl, 1 mM EDTA, and a protease inhibitor mixture (Nacalai)]. To detect binding between endogenous p53 and Mdm2, or The amount of p53 protein was determined as described in Fig. 1d . Gli1 and Gli2 expression was determined by immunoblotting, using antibodies against each tag. ( f) p53 and SMO-M2 expression plasmids were transfected into C3H10T1/2 cells with or without the Myc-tagged SuFu expression plasmid (40) . Forty-eight hours after transfection, the amount of p53 protein was determined by immunoblotting. The expression of SuFu was also determined by using antiMyc-tag antibody. (g) The Flag-tagged Hdm2 expression vector was transfected into C3H10T1/2 cells, and the cells were incubated with 1 g/ml Shh-N for 48 h. To inhibit protein synthesis, 80 g/ml cycloheximide (CHX) was added to the culture, which was then incubated for 2 h before harvest. Detection of phosphorylated Hdm2 was performed as described in a.
phosphorylation of Mdm2 and Akt, cells were lysed in lysis buffer [0.5% Nonidet P-40, 150 mM NaCl, 10 mM Tris⅐HCl (pH 8.0), 1 mM EDTA, 1 mM NaF, 1 mM orthovanadate 0.1 mM DTT, and a protease inhibitor mixture].
Immunoprecipitation was carried out as described in ref. 38 . Total cell lysate protein was quantified by using a protein assay kit (Bio-Rad), and an equal amount of protein was used for immunoprecipitation and immunoblotting. Additional materials and methods are provided in supporting information (SI) Materials and Methods. 
